These extensive, long-term studies not only indicate a causative role of hepatic oxalate overproduction in MASH, but also highlight the therapeutic potential of targeting AGXT, GO and LDHA to lower hepatic oxalate overproduction for the treatment of MASH. This evidence concerns the gene LDHA and metabolic dysfunction-associated steatohepatitis.